---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-24-000008"
form_type: "8-K"
ticker: null
cik: "0001602078"
company_name: "Nemaura Medical Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:41:14.119676+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Nemaura Medical accepts Nasdaq delisting, moves to OTC Markets; suspension Jan 5, 2024

## Summary
- Board and management strategically decided to accept Nasdaq's determination to delist the company.
- Received written notice from Nasdaq Hearings Panel on January 3, 2024, confirming delisting.
- Trading on Nasdaq suspended effective January 5, 2024; company will not request review.
- Shares expected to trade on OTC Markets following suspension.

## SEC filing metadata
- accession: 0001079973-24-000008
- form_type: 8-K
- cik: 0001602078
- company_name: Nemaura Medical Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1602078/000107997324000008/0001079973-24-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1602078/000107997324000008/nmra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-24-000008
- JSON: https://secwatch.observer/filing/0001079973-24-000008.json
- Plain text: https://secwatch.observer/filing/0001079973-24-000008.txt

## Key facts
- Listing & Compliance Notices
  Nemaura Medical Inc. received a nasdaq delisting notice notice regarding other.
  - Exchange: nasdaq
  - Notice: delisting notice
  source text: January 3, 2024, Nemaura Medical Inc. (the “Company”) issued a press release providing a crucial update regarding recent decisions that will impact the Company's listing status on The Nasdaq Capital Market and its broader strategic direction. Among other things, the press release indicated that, after thorough analysis, the Company’s Board of Directors and its management team have made the strategic decision to accept Nasdaq’s determination to delist the Company and move to the OTC Markets. Subsequently, on January 3, 2024, the Company received written notice from Nasdaq indicating that the Na
  evidence_url: https://www.sec.gov/Archives/edgar/data/1602078/000107997324000008/0001079973-24-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.